Last reviewed 2026-04-19 · How we verify

PIPENZOLATE

Phase 2 active Small molecule

PIPENZOLATE is a pipenzolate drug. It is currently in Phase 2 development.

Pipenzolate works by blocking the action of acetylcholine, a neurotransmitter that plays a key role in muscle contraction and other bodily functions.

Pipenzolate is a small molecule drug in the pipenzolate class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown, and it has not been approved by the FDA for any indications. Pipenzolate's commercial status, including whether it is patented or generic, and its availability from generic manufacturers, are also unknown. As a result, its half-life, bioavailability, and key safety considerations are also unclear. Further research is needed to understand the properties and potential uses of pipenzolate.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PIPENZOLATE
Drug class	pipenzolate
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of acetylcholine like a messenger that tells muscles to contract. Pipenzolate blocks this messenger, which can help to relax muscles and reduce spasms. This can be helpful in treating conditions where muscles are overactive or spasmodic.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PIPENZOLATE CI brief — competitive landscape report
PIPENZOLATE updates RSS · CI watch RSS

Frequently asked questions about PIPENZOLATE

What is PIPENZOLATE?

PIPENZOLATE is a pipenzolate drug.

How does PIPENZOLATE work?

Pipenzolate works by blocking the action of acetylcholine, a neurotransmitter that plays a key role in muscle contraction and other bodily functions.

What drug class is PIPENZOLATE in?

PIPENZOLATE belongs to the pipenzolate class. See all pipenzolate drugs at /class/pipenzolate.

What development phase is PIPENZOLATE in?

PIPENZOLATE is in Phase 2.

Drug class: All pipenzolate drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing